Review

An Atomic-Level Perspective of HMG-CoA-Reductase: The Target Enzyme to Treat Hypercholesterolemia

Diana S. Gesto 1, Carlos M. S. Pereira 2, Nuno M. F. S. Cerqueira 2 and Sérgio F. Sousa 2,*

1 UCIBIO, Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, 2829-516 Caparica, Portugal; dsgesto@fct.unl.pt
2 UCIBIO/REQUIMTE, BioSIM, Departamento de Biomedicina, Faculdade de Medicina da Universidade do Porto, Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal; pereira.cmsp94@gmail.com (C.M.S.P.); nunoscerqueira@med.up.pt (N.M.F.S.C.)
* Correspondence: sergiofsousa@med.up.pt

Abstract: This review provides an updated atomic-level perspective regarding the enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoAR), linking the more recent data on this enzyme with a structure/function interpretation. This enzyme catalyzes one of the most important steps in cholesterol biosynthesis and is regarded as one of the most important drug targets in the treatment of hypercholesterolemia. Taking this into consideration, we review in the present article several aspects of this enzyme, including its structure and biochemistry, its catalytic mechanism and different reported and proposed approaches for inhibiting this enzyme, including the commercially available statins or the possibility of using dimerization inhibitors.

Keywords: HMG-CoAR; structure; biochemistry; regulation; statins; dimerization inhibitors.

1. Introduction

Cholesterol (Figure 1) is a molecule of vital importance to most life forms and an essential structural component of eukaryotic cells. Nevertheless, this compound is commonly associated with several heart conditions, which leads to a public perception of cholesterol as an “evil” molecule.

![Figure 1. (a) 2D; and (b) 3D structures of the cholesterol molecule.](https://example.com/figure1.png)

The chemical structure of this sterol, with the formal name cholest-5-en-3β-ol, was firstly determined in 1932 by Windaus [1]. This molecule, along with other sterols, contains a core...
cyclopentanoperhydrophenanthrene ring system (i.e., four fused rings, three of which are six-carbon rings and one with five carbons) and is planar, rigid and water insoluble, due its large hydrophobic hydrocarbon body. Cholesterol is also an amphiphilic molecule due to its hydrophilic head, which includes the hydroxyl group [2,3]. These properties allow this compound to be the major sterol present in animal tissues and to play a vital role in the proper functioning of our cells. Besides being an important structural lipid that can be found in the cellular membrane of most eukaryotic cells, cholesterol also works as a precursor to several steroid hormones [3,4].

Membranes, at a cellular level, are responsible for the separation of the cytosol from the external medium. They comprise very different components, although in a simplistic way they can be represented as a double layer of phospholipids. These complex systems also allow the transference of compounds through them and carry out other important functions.

The importance of cholesterol in cellular membranes can be estimated by comparing the fluidity of membranes with their cholesterol content. As cholesterol is a somewhat rigid molecule, membranes with a higher cholesterol composition tend to be more rigid and packed, and those with less tend to be more fluid [2]. The fluidity of membranes is diminished not only due to the rigidity of cholesterol, but can also be influenced by the interaction of this molecule with the different membrane lipids (e.g., the creation of cholesterol–sphingolipid rafts makes membranes slightly thicker and more ordered) [3,5]. Additionally, this membrane lipid also aids the cell in other homeostasis processes, such as endocytosis [3].

As mentioned above, cholesterol is also a precursor of natural steroid hormones produced in our body, providing them with their core ring system, such as the hormones produced in the adrenal gland and the sex hormones (Figure 2).

Figure 2. 2D structures of: (a) cholesterol; and some of its precursors: (b) aldosterone; (c) cortisol; (d) testosterone; (e) progesterone; and (f) vitamin-D3.

The adrenal gland is located just above the kidneys and its main role is to produce and release two classes of hormones: corticosteroids and catecholamines. Only corticosteroid hormones are derived from cholesterol, and these can be further divided into two different classes: mineralocorticoids
and glucocorticoids. Mineralocorticoids (e.g., aldosterone (Figure 2b)) are hormones related to the reabsorption of ions such as Cl\(^-\), Na\(^+\) and HCO\(_3\)- by the kidney. On the other hand, glucocorticoids (e.g., cortisol (Figure 2c)) are a centerpiece for the metabolism of carbohydrates in the body, being responsible for the regulation of the levels of glucose. Both male and female sex glands also produce molecules that can be derived from cholesterol. These can be divided into androgens, such as testosterone (Figure 2d), which are responsible for the development of male characteristics, and estrogens and progestogens (Figure 2e), which are responsible for the development of female characteristics. Additionally, cholesterol can also be used as a precursor in the synthesis of bile salts and vitamin D (Figure 2f) [3,4].

Cholesterol present in our bodies derives from two different sources: it can be either synthesized de novo in our cells or obtained through the ingestion and absorption of certain foods, such as beef and pork meat, eggs and cheese. Although many people regularly eat these foods, there really is no absolute need to ingest them for the sole purpose of obtaining more cholesterol, since cholesterol homeostasis is regulated by the interplay between de novo synthesis/ingestion and the excretion or conversion of cholesterol into bile acids [6,7]. This means that, when low quantities of cholesterol are ingested, absorption and synthesis will be upregulated. Likewise, if the dietary intake is high, its excretion will increase [6,7]. This is a simplified approach to the cholesterol regulation mechanism, as it can change with several other external factors, e.g., aging [8]. As mentioned above, cholesterol has gained a bad reputation among the general population, especially due to its association with cardiovascular diseases (CVD). According to the World Health Association (WHO), CVDs accounted for 31% of the 57 million deaths that occurred in 2016 [9]. In the top 10 leading causes of death (worldwide) in 2016, ischemic heart disease (IHD) was number one, accounting for 16.6% of total deaths, followed by stroke and other cerebrovascular diseases (10.2%) [10]. The association between these diseases with hypercholesterolemia leads to a strong perception of cholesterol as a malignant compound by the general public.

Cholesterol is known to be associated with atherosclerosis, which is one of the main causes of CVDs [7,11]. Atherosclerosis derives from the accumulation of plaque, composed by fat, cholesterol, calcium and other substances found in the bloodstream, on the inside walls of arteries [12–14]. It is a complex process, which involves a chronic inflammatory response on the walls of arteries to oxidized low-density lipoproteins (LDL). This leads to a pathogenic accumulation of LDL in blood vessels and the formation of atherosclerotic plaques, which results in the constriction of blood vessels [12,13]. Lipoproteins are produced by our body in order to dilute cholesterol and other fats, which are water-insoluble, in our bloodstream. With the aid of apolipoproteins, it is possible to package these insoluble materials into protein-covered molecular assemblies. However, whenever there is a higher lipid content in these complexes, LDL (the often called “bad cholesterol”) is formed.

Even though CVDs are associated with the cholesterol content, it is important to note that high levels of cholesterol are not directly the cause of these diseases, and that people with the inability to produce this molecule have serious diseases, such as Smith–Lemli–Opitz syndrome and desmosterolosis [7,11].

2. Biosynthesis of Cholesterol and the Role of HMG-CoA

Cholesterol synthesis (Figure 3) is performed by multiple cells in the human body, whenever the cholesterol content attained by ingestion is low. This complex process is normally performed in the cytoplasm, and the major contributors are the liver and intestinal tissues. The cells are, by themselves, capable of producing enough cholesterol for our needs [15–17]. This process is heavily regulated at several points throughout its progression, and the reaction intermediaries can be deviated to the production of other compounds and to perform other body functions [18]. This process requires several steps, which can be summarized in four stages: synthesis of mevalonate (Figure 3a); conversion of mevalonate to activated isoprenes (Figure 3b); formation of squalene (Figure 3c); and ring closure of squalene to form the sterol ring system (Figure 3d) [19,20].
In a more detailed mechanism, the synthesis of cholesterol starts with the condensation of two acetyl-coenzyme A (acetyl-CoA) molecules to form the intermediate acetoacetyl-CoA. This process is catalyzed by a thiolase enzyme, known as acetyl-CoA acetyltransferase (ACAT). Hereinafter, the reaction of two acetoacetyl-CoA molecules catalyzed by HMG-CoA synthase (HMG-CoAS) allows for the formation of 3 hydroxy-3-methylglutaryl CoA (HMG-CoA), which is subsequently reduced to mevalonate by the enzyme HMG-CoA reductase (HMG-CoAR) and two NADPH molecules that function as cofactors (Figure 4). This latter reaction is the rate-limiting step of the overall synthesis of cholesterol, and it has been extensively studied since it defines the course of the reaction, known as the committed step, using HMG-CoAR as a regulatory enzyme.

The next step in the biosynthesis of cholesterol is the conversion of the intermediate mevalonate into two activated isoprenoids—isopentenyl-5-pyrophosphate and dimethylallyl pyrophosphate (IPP)—by the addition of three ATP molecules (Figure 3b). The obtained isoprenoids are used to synthesize several biomolecules, such as cholesterol, ubiquinone and sterol-based hormones in animals; carotenoids in plants; and cell-wall components (such as undecaprenyl phosphate) in eubacteria [19,21–25].

A successive condensation reaction of activated isoprenes allows for the formation of a 30-carbon molecule, known as squalene (Figure 3c), whose linear structure can be linked to the cyclic steroids and act as the biochemical precursor of all steroids. The synthesis of cholesterol is achieved by the mono
oxidation of squalene into an epoxide using a NADPH molecule, followed by the cyclization of the intermediate to form a 4-ring compound, the lanosterol molecule, which is converted into cholesterol after multiple subsequent reactions.

Since cholesterol biosynthesis is an energetically complex and expensive process (involves 18 ATP molecules), it is only natural to assume that it is carefully regulated. In mammals, its regulation is controlled by the intracellular cholesterol concentration and the presence of the hormones insulin and glucagon [19]. As mentioned above, the most important checkpoint is the conversion of HMG-CoA to mevalonate, a step catalyzed by HMG-CoAR. The importance of this enzyme to the mevalonate pathway has been evaluated through various experimental works, such as the work of Chappell et al., in which, after introducing a constitutively expressed HMG-CoAR gene from a hamster into tobacco plants, the activity of the enzyme became unregulated and the accumulation of sterols increased 3–10-fold [26]. The studies surrounding this enzyme were performed to assess not only its importance in the biosynthesis of cholesterol and other steroids, but also to understand how it works and is regulated.

3. Structure of HMG-CoA Reductase

HMG-CoAR is a very important enzyme in the production and regulation of several essential compounds. As discussed above, mevalonate will lead to the formation of isoprenoids, which are a metabolite of major importance in several different organisms, ranging from bacteria to plants and animals [21,27]. For this reason, these organisms also have similar enzymes that perform analogous reactions. HMG-CoAR can be found in eukaryotes and some prokaryotes, with some differences observed. With a sequence analysis of this protein, it was possible to point out two different classes. Class I enzymes (EC: 1.1.1.34) are present in most archaea and eukaryotes and are inserted in the membrane of the endoplasmic reticulum (ER) [27,28]. Class II HMG-CoAR (EC: 1.1.1.88), on the other hand, is completely soluble in the cytoplasm and is found in some archaea and prokaryotes [29].

In a more detailed view, Class I enzymes have a transmembrane domain, ranging from residues 1 to 339; a cytosolic domain in which the active site is located (residues 460–888); and are connected by a linker region, which is comprised by residues 340–459 (the description of the residues is associated with human protein) [30]. Class II contains only the catalytic domain of the Class I enzyme, thus resulting in a 428-residue polypeptide [31–33]. This results in sequence identities ranging 14–20% [27,30,33]. Despite this low sequence homology between classes, as well as a different protein architecture, both enzymes have comparable positions for the active sites residues and a highly conserved catalytic portion (Figure 5) [30,33]. The study that led to the early development and understanding of the mevalonate pathway used this feature, as the first Class II HMG-CoAR enzyme was obtained from the eubacterium Pseudomonas mevalonii [34,35]. This enzyme was a useful model for the characterization of the active site residues, even preceding crystallographic information [34–38].

| Class I          | 559 | 691 | 735 | 767 | 866 |
|------------------|-----|-----|-----|-----|-----|
| Human            | PMATGSLVA | NYCTDXXPAAI | IGGYNAHAANI | IAGGAAQ&V | HLKSHMIHNR |
| Bovine           | PMATGSLVA | NYCTDXXPAAI | IGGYNAHAANI | IAGGAAQ&V | HLKSHMIHNR |
| Rabbit           | PMATGSLVA | NYCTDXXPAAI | IGGYNAHAANI | IAGGAAQ&V | HLKSHMIHNR |

| Class II         | 83  | 221 | 267 | 283 | 381 |
|------------------|-----|-----|-----|-----|-----|
| P. mevalonii     | PLAVTEPSIVA | NLADLRLARAQ | AATKNKIMNG | VATGNDRAVE | GITQGSMXMA |
| S. aureus        | PMVMTEPSVIA | NHATASVVKKVQ | AATKNKBMNG | VAFGNGRAVE | GITQGSMXLOK |
| S. salivarius    | PMVTTEPSVIA | NLLATELSLYTAT | AATKNKIFNG | IATGNDRAVE | GITQAGMKLOQA |
| L. quinivariani  | PLAVTEPSIVA | NLNDQTLTAK | AATKNKBMNG | IATGNDRAVE | GITQGSMXMRNL |

Figure 5. HMGCRs sequence alignment around the main catalytic residues, which are highlighted in yellow. The numbering is related to the human enzyme for Class I and with the Pseudomonas mevalonii one for Class II. Residues colored in grey are conserved between classes and those colored in light blue are conserved within the same class.
The tridimensional structural information for the human HMGCR (Figure 6) was solved for the first time in 2000 by Istvan et al. [38]. Currently, there are 22 structures for the catalytic domain of the human enzyme available on the Protein Data Bank, which sum up to more than 40 if we also count those from other organisms. These structures contain those of the enzyme alone as well as complexes between HMGCR and HMG-CoA, NADP+ and different statins (Table 1).

Figure 6. Structure of the tetramer and respective dimer of the human HMGCR, showing both CoA and NADPH (PDB entry 1DQA); chains are colored according with the letters: chain A is in magenta, chain B in blue, chain C in light green and chain D in orange.

Table 1. Currently known HMGCR crystal structures available in the Protein Data Bank, organized chronologically, starting with the most recently available.

| PDB     | Organism                        | Year | Resolution (Å) | Chain Length | Ligand(s)      | Ref. |
|---------|---------------------------------|------|----------------|--------------|----------------|-----|
| 6HR8    | Methanothermococcus thermolithotrophicus | 2019 | 2.9            | 427          | NADPH, PEG     | [39]|
| 6HR7    |                                   |      | 2.4            | 427          | P6G, DTT       |     |
| 6EEV    | Delftia acidovorans             | 2018 | 1.5            | 429          | MEV            | [40]|
| 6EEU    |                                   |      | 1.9            | 429          | -              |     |
| 6DIO    |                                   |      | 2.1            | 429          | NAD            |     |
| 5WPK    | Streptococcus pneumoniae        | 2018 | 2.3            | 426          | PE4, HMG      | [41]|
| 5WPJ    |                                   |      | 2.0            | 426          | NADPH          |     |
| 46Y     | Pseudomonas mevalonii           | 2013 | 1.5            | 428          | MEV            |     |
| 46W     |                                   |      | 1.7            | 428          | 1CO           |     |
| 46A     |                                   |      | 1.9            | 428          | HMG            | [21]|
| 46D     |                                   |      | 1.8            | 428          | -              |     |
| 456     |                                   |      | 1.5            | 428          | 1CZ            |     |
| 4HB     |                                   |      | 1.7            | 428          | NAD, 1CO, 1CV |     |
| 3QAU    | Escherichia coli                | 2011 | 2.3            | 458          | -              | n.a.|
| 3QAE    |                                   |      | 2.3            | 458          | -              |     |
| 3CDB    | Homo sapiens                    | 2008 | 2.3            | 441          | 9HI            |     |
| 3CDA    |                                   |      | 2.1            | 441          | 8HI            |     |
| 3CD7    |                                   |      | 2.1            | 441          | 882            | [42]|
| 3CD5    |                                   |      | 2.4            | 441          | 7HI            |     |
| 3CD0    |                                   |      | 2.4            | 441          | 6HI            |     |
| 3CCZ    | Homo sapiens                    |      | 1.7            | 441          | 5HI            |     |
| 3CCW    |                                   |      | 2.1            | 441          | 4HI            | [42]|
| 3CCT    |                                   |      | 2.1            | 441          | 3HI            |     |
Table 1. Cont.

| PDB  | Organism            | Year | Resolution (Å) | Chain Length | Ligand(s) | Ref.     |
|------|---------------------|------|----------------|--------------|-----------|----------|
| 2R4F | Homo sapiens        | 2008 | 1.7            | 441          | RIE       | [43]     |
| 3BGL | Homo sapiens        | 2008 | 2.2            | 441          | RID       | [44]     |
| 2Q6C | Homo sapiens        | 2007 | 2.0            | 441          | HR1       |          |
| 2Q6B | Homo sapiens        | 2007 | 2.0            | 441          | HR2       | [45]     |
| 2Q1L |                     |      | 2.1            | 441          |           |          |
| 1T02 | Pseudomonas mevalonii | 2003 | 2.6            | 428          | Lovastatin | [46]     |
| 1R7I | Pseudomonas mevalonii | 2003 | 2.2            | 428          |           | n.a.     |
| 1R31 |                     | 2003 | 2.1            | 428          | MEV, CoA  |          |
| 1HWL |                     |      | 2.1            | 467          | ADP, Rosuvastatin | |
| 1HWK |                     |      | 2.2            | 467          | ADP, Atrvastatin | |
| 1HWJ |                     |      | 2.3            | 467          | ADP, Cerivastatin | |
| 1HWI | Homo sapiens        | 2001 | 2.3            | 467          | ADP, Fluvastatin | [47]     |
| 1HW9 |                     |      | 2.3            | 467          | ADP, Simvastatin | |
| 1HW8 |                     |      | 2.1            | 467          | ADP, Compactin | |
| 1DQA | Homo sapiens        | 2000 | 2.0            | 467          | MAH, CoA, NADP | [38]     |
| 1DQ9 |                     |      | 2.8            | 467          | HMG       | [38]     |
| 1DQ8 |                     |      | 2.1            | 467          | CoA, DTT, MAH | |
| 1QAY | Pseudomonas mevalonii | 1999 | 2.8            | 428          | MEV, NAD  | [48]     |
| 1QAX |                     |      | 2.8            | 428          | HMG, NAD  |          |

As referred above, the Class I protein is divided in three different domains: the membrane-anchor, a linker and a catalytic domain. From the human HMGCR structures, which only include the catalytic domain, it is possible to observe a tetramer produced by four identical monomers. The monomers form dimers in which each subunit is coiled around the other in an intricate way. Each tetramer contains four active sites, two in each dimer, which are made up of residues from both subunits. The monomer itself can be divided into three different subdomains (Figure 7): A small, α-helical amino-terminal N-domain, residues 460–527; a large central L-domain that binds to HMG-CoA, residues 528–590 and 694–872 (Figure 7b); and a small carboxyl-terminal S-domain that binds to NADPH, residues 591–682 (Figure 7c) [30,33,49,50].

The dimer interfaces are extensive, and all domains of the monomer participate in interactions that join the subunits together. The most broad interactions are located in the three following regions (Figure 8): (i) the loop that connects the L-domain and the S-domain, residues 682–694, called the cis-loop, which is essential for the formation of the HMG-binding site and the connection with the NADPH-binding region; (ii) the region in the L-domain where an intramolecular β-sheet is formed, and the two strands of this β-sheet are characterized by a highly conserved sequence, ENVIGX3I/LP; and (iii) a four α-helix bundle formed by helices Lα6 and Lα7 (two from each monomer), which fold in an antiparallel fashion with the corresponding helices from the neighboring and equivalent subunit [49].

The core active site of this enzyme for the reduction of HMG-CoA is found in the cis-loop, and the key catalytic residues are Lys691, Glu559, Asp767 and His866 [30,33].

Despite the fact that the HMG-CoAR tetramer was only observed on crystallized structures of the catalytic domain alone, other studies suggest that this configuration is maintained even in the full-length human HMG-CoAR, containing both catalytic and transmembrane domains [38]. In the full-length protein, the N-domain is essential for establishing the connections between the catalytic portion of HMG-CoAR and the membrane domain [30,38].
Contrary to the catalytic portion of the HMG-CoAR, the transmembrane domain is not very well conserved in eukaryotes (Figure 9). In mammals, the membrane spanning region forms eight helices that are inserted in the membrane; contrarily, plants and yeast contain two and seven, respectively [38]. Mammalian enzymes contain a 167-residue segment which is sensitive to sterols. This segment has a sequence identity of approximately 25% with other cholesterol-related membrane proteins that sense cholesterol abundance or transport cholesterol [49,51–54].
Figure 9. Representation of the conservation score obtained for the catalytic portion of human HMG-CoA Reductase (PDB code 1DQA), using the software ConSurf-DB [55]. It is possible to observe in magenta highly conserved residues, typically with some structural and/or functional importance; the residues with low conservation are in cyan.

Active Site Architecture and Catalytic Mechanism of HMG-CoA Reductase

The description of the active site of HMG-CoA Reductase, enzyme responsible for the reduction of HMG-CoA to mevalonate, is briefly depicted above. In short, the active site of this enzyme is formed by two different subunits that form a dimer when bound together. The catalytic domain remains unchanged even with the formation of the tetramer.

The active site of the HMG-CoA Reductase enzyme is a large cavity which is located at the monomer–monomer interface. This active site can be divided into three different binding subsites: one for HMG, one for CoA and one for NADPH.

The binding site of CoA (Figure 10B) is positioned in the L-domain of one monomer. The ADP moiety of CoA binds near the surface of the enzyme, in a pocket lined with positively charged residues. The residues that are involved in the CoA binding pocket are Ser565, Asn567, Arg568, Lys722, Ser865, His866 and Tyr479 (this last residue comes from the neighboring monomer). The side chain of Tyr479 is of particular importance, as it interacts with the adenine base of CoA through π–π stacking while its hydroxyl group makes a hydrogen bond with the 3′-phosphate of the ribose moiety [49].

The NADPH (Figure 10C) binds to the S-domain of the opposing subunit in which the HMG-CoA binding pocket is located. Residues Ser626, Arg627, Phe628, Asp653, Met655, Gly656, Met657, Asn658 and Val805 come from the S-domain and residues Asn870 and Arg871 from the neighboring monomer. In the presence of NADPH, a conformational change in the C-terminus of the enzyme is observed which leads to the closure of the active site [49].

Lastly, the HMG binding site (Figure 10A) is located at the interface of the two monomers. This binding pocket is formed by residues Ser684, Asp690, Lys691, Lys692 and Asp767 from one subunit and Glu559, Lys735, Asn755, Leu853 and His866 from the other. This is also the catalytic site of the enzyme. The currently accepted mechanism of HMG-CoA is present in Figure 11.
Figure 10. Representation of: (A) the active site of HMG-CoAR; (B) the binding sites of the HMG portion of HMG-CoA; and (C) the binding sites of NADP (PDB entry 1DQ9).

The NADPH (Figure 10C) binds to the S-domain of the opposing subunit in which the HMG-CoA binding pocket is located. Residues Ser626, Arg627, Phe628, Asp653, Met655, Gly656, Met657, Asn658 and Val805 come from the S-domain and residues Asn870 and Arg871 from the neighboring monomer. In the presence of NADPH, a conformational change in the C-terminus of the enzyme is observed which leads to the closure of the active site [49].

Lastly, the HMG binding site (Figure 10A) is located at the interface of the two monomers. This binding pocket is formed by residues Ser684, Asp690, Lys691, Lys692 and Asp767 from one subunit and Glu559, Lys735, Asn755, Leu853 and His866 from the other. This is also the catalytic site of the enzyme. The currently accepted mechanism of HMG-CoA is present in Figure 11.

Figure 11. Currently accepted catalytic mechanism of HMG-CoAR [56]. The catalytic residues are Lys691, Glu559, Asp767 and His866; chain A is highlighted in pink and chain B is highlighted in blue. Glu559 and His866 are restored in a following step by deprotonation of adjacent water molecules.
As observed in the mechanism shown in Figure 11, the enzyme HMG-CoAR enables the reduction of thioesterified HMG-CoA to mevalonate, using two molecules of NADPH for successive hydride transfers. The first step results in the formation of mevaldyl-CoA hemi-thioacetal, followed by the formation of the mevaldehyde, which occurs with the collapse of the thiohemiacetal and formation of CoA-SH (protonation of the thiol anion by Hys866). In the final step, the second NADPH reduces mevaldehyde to mevalonate [20,27,33,48,49,56].

The perception of this complex mechanism has changed through the years. In an earlier work, Tabernero et al. proposed a similar mechanism to the one depicted in Figure 11 for the P. mevalonii enzyme, in which Lys267 was proposed to be the general acid that stabilizes the mevaldyl-CoA intermediate [48]. As shown in Figure 6 and their work, it is not obvious to find the correct association between this residue from P. mevalonii and other HMG-CoARs using sequence homology. This was also observed by Haines et al., as their alignment is different from ours and the previous work [27]. In this latter work, they observed that the reduction of mevaldyl-CoA was performed with the aid of Glu83 (which is equivalent to Glu559 in the human enzyme), instead of Lys267. This work is supported by the position of the active site human residues as: (i) negatively charged intermediates can be stabilized by the positive charge of Lys691; (ii) the proximity between one of the side chain oxygens of Glu559 and the carbonyl oxygen of HMG suggests that this residue is protonated; (iii) the negatively charged Asp767 plays a critical role, as it is close enough to the glutamate to influence its pKa value, as well as being able to stabilize through ionic interactions the Lys691 side chain in the active; and (iv) the His866 can make a hydrogen bond with CoA thiol [27]. The mechanism proposed in Figure 11 follows the line of an QM/MM study, in which several approaches were tested. Oliveira et al. concluded that the correct mechanism is similar to the one proposed by Tabernero, however some structural features of Haines were used [56]. The presence of a neutral Glu559 in the active site allows for this residue to be more distant from the positively charged Hys866, as Glu559 and Asp767 form a hydrogen bond. Thus, Glu599 is no longer in an appropriate position to stabilize the mevaldyl-CoA intermediate, as previously suggested [27]. From the models tested by Oliveira et al., the one with the neutral Glu599 presented the lowest activation free energy for the reaction mechanism in Figure 11, in which the protonation of mevaldyl-CoA is performed by Lys691 [56].

Considering the structural differences between both classes of HMG-CoAR, and, consequently the different positions of the catalytic residues, it is safe to assume that the reaction mechanisms will be different. P. mevalonii enzyme is responsible for the reverse reaction of the human variant, and it has been shown that it is possible for this prokaryote to grow on mevalonate only [57]. The cis-loop found in Class I reductases, which is key for the positioning of the catalytic residues, is missing in this version of the protein. Instead, the position of His381 (analogous to His866) is approximated to the active site by the closure of the flap domain, i.e., the C-terminal 50 residues of Class II. This motion also alters the binding of the substrate and the cofactor [49,58].

4. Regulation of HMG-CoAR

HMG-CoAR is one of the most regulated enzymes in our body. The regulation can be achieved in four different ways: transcription of the enzyme’s gene [59–64]; translation of its mRNA [65]; degradation of the functional enzyme [66–73]; and modulation of its activity [74–76].

The transcription of HMG-CoAR gene and the rate of synthesis of this enzyme is controlled by the sterol regulatory element binding proteins (SREBPs). These proteins are commonly anchored in the ER membrane in a complex that is coupled with another two proteins, the SREBP cleavage activating protein (SCAP) and insulin induced gene protein (INSIG). The latter two proteins act as sterol sensors and render SREBPs inactive when they are bound together [3,50,61]. The complexed form occurs when a high concentration of cholesterol (or other sterols) is present in the cell. SCAP binds to cholesterol, which leads to a structural change that is stabilized by the INSIG proteins present in the ER. Upon the decrease of the cellular concentration of sterols, INSIG unbinds SCAP, which in turn escorts SREBP, with the aid of secretory proteins, to the Golgi complex [51,62–64].
Inside the Golgi complex, SREBP is sliced in two positions by specific proteolytic cleavages. This cleavage releases the N-terminal basic helix-loop-helix domain, which is now free to enter the nucleus behaving as a transcriptional factor and is able to recognize certain sequences of DNA called sterol-regulatory elements (SRE). When this transcription factor binds to them, it promotes the transcription of the HMG-CoAR gene, as well as other proteins used for lipid synthesis [63–65].

In addition to the transcriptional regulation, HMG-CoAR is also regulated via post-translational mechanisms. Following the increase in cellular sterol content, the degradation of HMG-CoAR is activated. INSIG once again has a key role in this process. When the levels of sterol are high enough, both SCAP and HMG-CoAR compete to bind INSIG. When SCAP binds to SREBP, the proteolytic release is shut down, and, when HMG-CoAR binds to INSIG, Lys248 of the human HMG-CoAR is ubiquitinated and the protein is then quickly degraded through a ubiquitin-proteasome mechanism [66,67,75]. More recently, it has been suggested that C4-dimethylated sterol intermediates produced during the mevalonate pathway can suppress SREBP cleavage and promote HMG-CoAR degradation, whereas cholesterol is a relatively weak inducer [77,78].

The catalytic activity of HMG-CoAR can also be modulated by phosphorylation [79,80]. Next to His866, one of the active site residues, there is a Ser872, which can be phosphorylated. The phosphorylation of this residue leads to the decrease of the catalytic activity of HMG-CoAR, since it decreases the affinity of the enzyme to NADPH. The position of the serine, so close to the catalytic histidine, is well conserved in superior eukaryotes, which suggests that the phosphoserine can interfere with the ability of histidine to protonate coenzyme A thioanion before it is released from the active site [75,76]. Alternatively, it is supposed that the phosphoserine can also prevent the closure of a C-terminal region, which is responsible for facilitating catalysis. The subsequent dephosphorylation of this serine completely restores the catalytic activity of HMG-CoAR [38,49].

5. HMG-CoAR Inhibitors

To try to diminish the escalating number of deaths caused directly or indirectly by the high levels of blood cholesterol, researchers started to investigate the best way to help reduce these levels. In fact, simply controlling the ingestion of cholesterol containing food was not enough to control its concentration in the blood [47,81]. Initial treatments to hypercholesterolemia used several approaches, such as bile-acids sequestrants, nicotinic acid, fibrates and probucol. The search for better cholesterol lowering drugs was maintained, due to the relative low efficiency of these medications.

5.1. Statins: The Most Common Inhibitor

In the mid 1970s, compactin, the first HMG-CoAR inhibitor, was discovered by Endo and coworkers, and the drug was tested for its efficiency as a cholesterol lowering medicine [82–84]. As the results were favorable, development of new and improved statins rose exponentially and soon after statins became the most used drug to control high levels of blood cholesterol, thereby reducing heart attacks and prolonging life in humans with atherosclerosis [85–87].

Statins are potent competitive inhibitors of HMG-CoAR and can be divided in two types, according to their origin [49,88,89]. Type I statins (Figure 12b), e.g., lovastatin, pravastatin and simvastatin, are natural fungal products and Type II statins (Figure 12c) are fully synthetic. All statins have similar structures to HMG (Figure 12a) and are covalently linked to a rigid hydrophobic group. When administered, the HMG-like moiety of these drugs is in an inactive form, which is later hydrolyzed in-vivo by cellular enzymes, i.e., esterases [90]. Type II statins are characterized by the presence of larger hydrophobic regions and attached fluorophenyl groups, as it is possible to observe in Figure 12c [91].
which leads to a competition towards the HMG binding site of the enzyme between HMG-CoA and statins. Even though the hydrophobic part of statins differ greatly from CoA portion of the substrate, it also blocks the access of HMG-CoA to the binding site (Figure 13). Thus, the affinity of this enzyme for statins is slightly higher than its affinity for the substrate [92].

The ability of statins to inhibit HMG-CoAR arises from their similarity with the substrate, which leads to a competition towards the HMG binding site of the enzyme between HMG-CoA and statins. Even though the hydrophobic part of statins differs greatly from CoA portion of the substrate, it also blocks the access of HMG-CoA to the binding site (Figure 13). Thus, the affinity of this enzyme for statins is slightly higher than its affinity for the substrate [92].

The usage of statins may lead to some beneficial effects to the patients, such as plaque stabilization and anti-inflammatory and antithrombotic effects, among others [93]. These pleiotropic effects have

Figure 12. Structures of: (a) HMG-CoA; (b) Type I statins; and (c) Type II statins.

Figure 13. Demonstration of the active site residues when a statin (atorvastatin) is bounded (PDB code 1HWK): (a) only atorvastatin is presented in yellow; and (b) HMG-CoA is also bound to more easily compare the inhibitor with the natural substrate (PDB entry 1HWk and 1DQ9). These structures follow the representation and color code of the dimer in Figure 6, as chain A and B are colored in magenta and blue (transparent to better see details), respectively.
and continue to be studied to repurpose statins in the treatment of other diseases, such as cancer [94] and regeneration of bone defects [95]. Nevertheless, there are several adverse side effects linked to statins [96], including skeletal muscle-related toxicity, cataracts, vascular lesions in the central nervous system and testicular degeneration and new-onset type 2 diabetes mellitus [97–99], or even lethal ones, e.g., rhabdomyolysis. Fatalities due to this disease led to the withdrawal of cerivastatin from the market in 2001 [100]. The mechanisms through which these adverse effects develop is still not quite understood and remains a topic of debate to this day. It is suggested that many of these side effects are due to the depletion of mevalonate-derived intermediates, which is a direct consequence of the inhibition of HMG-CoAR and the interruption of the mevalonate pathway. Despite all the possible side effects, this did not preclude atorvastatin from being the one of the most profitable and prescribed drugs in the world this millennium, which demonstrates that high blood concentration of cholesterol is a very serious problem that humankind is facing today [101,102].

The research on the side effects derived from the prescription of statins has been one of the major objectives of researchers in recent years, and it has been demonstrated that these drugs are also beneficial in fighting diseases other than hypercholesterolemia. For example, the inhibition of HMG-CoAR and subsequent depletion of mevalonate-derived isoprene metabolites, which are essential for cell proliferation in both normal and tumor cells, has led to the conclusion that statins can be used as anticarciogenes [94,103–108]. In Alzheimer’s disease, the presence of hypertension, elevated plasma total cholesterol, low-density lipoprotein cholesterol levels (LDL) and atherosclerosis accelerate the progression and aggravate the symptoms. This means that, even though statins are usually prescribed to patients with high blood levels of cholesterol, they can also be a useful tool in the fight against other prevalent diseases [109,110].

5.2. Alternative Approaches

Statins have been used as the main inhibitors of HMG-CoAR for more than 30 years, despite the concerns that surround the adverse side effects that they can induce. However, there is still a need for further improvements in the treatment of hypercholesterolemia, which may or may not involve the usage of statins.

Several new methodologies have been reported for lowering blood cholesterol, which are focused on the inhibition of the synthesis of cholesterol [111–113], reducing its absorption [114–116], inducing reductase degradation [69–73] and limiting the synthesis of LDL [117–119]. SR-12813 and apomine (SR-45023A) are synthetic compounds that have been demonstrated to be powerful tools in this particular task by inducing HMG-CoAR degradation [69,70,72]. Another alternative is the chemical breakdown of HMG-CoAR using small-molecules proteolysis through the use chimeras (PROTACs) with subsequent inhibition in cholesterol production [73].

These approaches seem promising, and in the future one of them may become the preferred treatment, but currently the interruption of the mevalonate pathway through the inhibition of HMG-CoAR continues to be the most favored method.

Similar to statins, auranofin (AuRF), an anticancer agent, has been shown to inhibit HMG-CoAR, with half maximal inhibitory concentration at micromolar levels [120]. Peptide drugs, which are currently gaining more visibility in several therapeutic areas, have also shown some promising results as inhibitors of this enzyme, particularly the tetrapeptide PMAS, which has been shown to effectively inhibit HMG-CoAR (IC_{50} = 68 μM) [121]. It has also been demonstrated that meroterpenoids, ganoleucoins and triterpenes, compounds obtained from the medicinal mushroom *Ganoderma leucocontextum*, can have some activity towards the inhibition of this enzyme [122,123]. Infusions from *Vernonia condensata* Baker, and bay leaf (*Syzygium polianthum*) extracts, which were known to have the ability to reduce cholesterol levels, have also been a matter of study in recent years. In both cases, it was found that the preparations obtained from these plants contained compounds capable of binding HMG-CoAR and reducing its activity. In the case of *Vernonia condensata* Baker infusions, it was found this activity was due to caffeoylquinic acids [124], whereas, in the case of bay leaves, it was due to the presence of the phenolic
compounds present in the extracts [125]. While it is true that most of these molecules show IC$_{50}$ values much higher than that of common statins (in the micromolar range, as opposed to nanomolar for the statins), these can be a starting point for the study and introduction of a new class of statins.

Another interesting way to inhibit HMG-CoAR is by precluding the dimerization process. As discussed in Section 3, the enzyme consists of a “dimer of dimers”, in which each dimer contains two active sites. Therefore, preventing the formation of the different dimers avoids the formation of the active sites and, consequently, the formation of an active enzyme. To date, no dimerization inhibitors of HMG-CoAR are known, however there was a recent study that highlighted new druggable binding pockets that can be used for this purpose [126].

6. Conclusions

Cholesterol plays an essential role in cellular growth, membrane synthesis and differentiation. However, in the 1950s and 1960s, it became apparent that elevated concentrations of plasma cholesterol were a major risk factor for the development of coronary heart disease, which led to the early development of drugs that could reduce plasma cholesterol. One possibility was to reduce cholesterol biosynthesis, by inhibiting the rate-limiting enzyme in the cholesterol biosynthetic pathway, HMG-CoAR.

Currently, there is an impressive portfolio of studies regarding HMG-CoAR, and the details regarding the structure and catalytic mechanism of the enzyme are nowadays better understood.

Statins are the most popular HMG-CoAR inhibitors, particularly the fungal derivatives lovastatin, simvastatin and pravastatin and the synthetic fluvastatin and atorvastatin. These compounds are in the majority of cases well tolerated and have a finite and relatively safe side effect profile. Within the next few years, it is expected that statins will continue to be the main prescribed drug to treat hypercholesterolemia. However, the combination of statins with certain drugs can increase the risk of hepatotoxicity and myotoxicity effects, turning their use in some patients not favorable. Taking this into account, the development and application of new methods to inhibit HMG-CoAR is likely to play an increasingly important role in the treatment of hypercholesterolemia.

Author Contributions: Conceptualization, N.M.F.S.C. and S.F.S.; writing—original draft preparation, D.S.G. and C.M.S.P.; writing—review and editing, N.M.F.S.C. and S.F.S.; supervision, N.M.F.S.C. and S.F.S. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the Applied Molecular Biosciences Unit (UCIBIO), which is financed by national funds from FCT (UIDB/04378/2020), as by the RSB-TS project (PTDC/QUI-QFI/31689/2017).

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Windaus, A. Über die konstitution des cholesterins und der gallensäuren. Biol. Chem. 1932, 213, 147–187. [CrossRef]
2. Sheppard, A.J.; O’Dell, R.G.; Pennington, J.A.T. CHOLESTEROL | Properties and determination. In Encyclopedia of Food Sciences and Nutrition, 2nd ed.; Caballero, B., Ed.; Academic Press: Oxford, UK, 2003; pp. 1220–1226. ISBN 978-0-12-227055-0.
3. Nelson, D.L.; Lehninger, A.L.; Cox, M.M. Lehninger Principles of Biochemistry; W.H. Freeman: New York, NY, USA, 2008; ISBN 9781429208925.
4. Arnold, D.R.; Kwiterovich, P.O. CHOLESTEROL | Absorption, Function, and Metabolism. In Encyclopedia of Food Sciences and Nutrition, 2nd ed.; Caballero, B., Ed.; Academic Press: Oxford, UK, 2003; pp. 1226–1237. ISBN 978-0-12-227055-0.
5. Maxfield, F.R.; van Meer, G. Cholesterol, the central lipid of mammalian cells. Curr. Opin. Cell Biol. 2010, 22, 422–429. [CrossRef] [PubMed]
6. Lecerf, J.M.; de Lorgeril, M. Dietary cholesterol: From physiology to cardiovascular risk. Br. J. Nutr. 2011, 106, 6–14. [CrossRef] [PubMed]
7. Alphonse, P.A.S.; Jones, P.J.H. Revisiting human cholesterol synthesis and absorption: The reciprocity paradigm and its key regulators. Lipids 2016, 51, 519–536. [CrossRef]
8. McAuley, M.T.; Wilkinson, D.J.; Jones, J.J.; Kirkwood, T.B. A whole-body mathematical model of cholesterol metabolism and its age-associated dysregulation. BMC Syst. Biol. 2012, 6, 130. [CrossRef]
9. WHO. Noncommunicable Diseases Country Profiles 2018; WHO: Geneva, Switzerland, 2018; ISBN 978-92-4-151462-0.
10. Global Health Estimates 2016: Deaths by Cause, Age, Sex, by Country and by Region. Available online: https://www.who.int/healthinfo/global_burden_disease/estimates/en/ (accessed on 12 January 2020).
11. Ravnskov, U.; de Lorgeril, M.; Diamond, D.M.; Hama, R.; Hamazaki, T.; Hammarskjold, B.; Hynes, N.; Kendrick, M.; Langsjoen, P.H.; Mascitelli, L.; et al. LDL-C does not cause cardiovascular disease: A comprehensive review of the current literature. Expert Rev. Clin. Pharmacol 2018, 11, 959–970. [CrossRef]
12. Libby, P. Inflammation in atherosclerosis. Nature 2002, 420, 868–874. [CrossRef]
13. Matsumoto, Y.; Yasukawa, J.; Ishii, M.; Hayashi, Y.; Miyazaki, S.; Sekimizu, K. A critical role of mevalonate metabolism and its age-associated dysregulation. BMC Syst. Biol. 2012, 6, 130. [CrossRef]
14. Goldstein, J.L.; Brown, M.S. Regulation of the mevalonate pathway. Nature 1984, 310, 347–352. [CrossRef]
15. Libby, P. Inflammation in atherosclerosis. Circ. Res. 2019, 124, 315–327. [CrossRef]
16. Hussain, M.M.; Strickland, D.K.; Bakillah, A. The mammalian low-density lipoprotein receptor family. Annu. Rev. Nutr. 1999, 19, 141–172. [CrossRef]
17. Hussain, M.M.; Strickland, D.K.; Bakillah, A. The mammalian low-density lipoprotein receptor family. Annu. Rev. Nutr. 1999, 19, 141–172. [CrossRef]
18. Hussain, M.M.; Strickland, D.K.; Bakillah, A. The mammalian low-density lipoprotein receptor family. Annu. Rev. Nutr. 1999, 19, 141–172. [CrossRef]
19. Hussain, M.M.; Strickland, D.K.; Bakillah, A. The mammalian low-density lipoprotein receptor family. Annu. Rev. Nutr. 1999, 19, 141–172. [CrossRef]
20. Hussain, M.M.; Strickland, D.K.; Bakillah, A. The mammalian low-density lipoprotein receptor family. Annu. Rev. Nutr. 1999, 19, 141–172. [CrossRef]
21. Hussain, M.M.; Strickland, D.K.; Bakillah, A. The mammalian low-density lipoprotein receptor family. Annu. Rev. Nutr. 1999, 19, 141–172. [CrossRef]
22. Hussain, M.M.; Strickland, D.K.; Bakillah, A. The mammalian low-density lipoprotein receptor family. Annu. Rev. Nutr. 1999, 19, 141–172. [CrossRef]
23. Hussain, M.M.; Strickland, D.K.; Bakillah, A. The mammalian low-density lipoprotein receptor family. Annu. Rev. Nutr. 1999, 19, 141–172. [CrossRef]
24. Hussain, M.M.; Strickland, D.K.; Bakillah, A. The mammalian low-density lipoprotein receptor family. Annu. Rev. Nutr. 1999, 19, 141–172. [CrossRef]
25. Hussain, M.M.; Strickland, D.K.; Bakillah, A. The mammalian low-density lipoprotein receptor family. Annu. Rev. Nutr. 1999, 19, 141–172. [CrossRef]
26. Hussain, M.M.; Strickland, D.K.; Bakillah, A. The mammalian low-density lipoprotein receptor family. Annu. Rev. Nutr. 1999, 19, 141–172. [CrossRef]
27. Hussain, M.M.; Strickland, D.K.; Bakillah, A. The mammalian low-density lipoprotein receptor family. Annu. Rev. Nutr. 1999, 19, 141–172. [CrossRef]
28. Hussain, M.M.; Strickland, D.K.; Bakillah, A. The mammalian low-density lipoprotein receptor family. Annu. Rev. Nutr. 1999, 19, 141–172. [CrossRef]
29. Hussain, M.M.; Strickland, D.K.; Bakillah, A. The mammalian low-density lipoprotein receptor family. Annu. Rev. Nutr. 1999, 19, 141–172. [CrossRef]
30. Hussain, M.M.; Strickland, D.K.; Bakillah, A. The mammalian low-density lipoprotein receptor family. Annu. Rev. Nutr. 1999, 19, 141–172. [CrossRef]
31. Hussain, M.M.; Strickland, D.K.; Bakillah, A. The mammalian low-density lipoprotein receptor family. Annu. Rev. Nutr. 1999, 19, 141–172. [CrossRef]
32. Hussain, M.M.; Strickland, D.K.; Bakillah, A. The mammalian low-density lipoprotein receptor family. Annu. Rev. Nutr. 1999, 19, 141–172. [CrossRef]
33. Hussain, M.M.; Strickland, D.K.; Bakillah, A. The mammalian low-density lipoprotein receptor family. Annu. Rev. Nutr. 1999, 19, 141–172. [CrossRef]
34. Hussain, M.M.; Strickland, D.K.; Bakillah, A. The mammalian low-density lipoprotein receptor family. Annu. Rev. Nutr. 1999, 19, 141–172. [CrossRef]
35. Hussain, M.M.; Strickland, D.K.; Bakillah, A. The mammalian low-density lipoprotein receptor family. Annu. Rev. Nutr. 1999, 19, 141–172. [CrossRef]
36. Hussain, M.M.; Strickland, D.K.; Bakillah, A. The mammalian low-density lipoprotein receptor family. Annu. Rev. Nutr. 1999, 19, 141–172. [CrossRef]
37. Hussain, M.M.; Strickland, D.K.; Bakillah, A. The mammalian low-density lipoprotein receptor family. Annu. Rev. Nutr. 1999, 19, 141–172. [CrossRef]
38. Hussain, M.M.; Strickland, D.K.; Bakillah, A. The mammalian low-density lipoprotein receptor family. Annu. Rev. Nutr. 1999, 19, 141–172. [CrossRef]
39. Hussain, M.M.; Strickland, D.K.; Bakillah, A. The mammalian low-density lipoprotein receptor family. Annu. Rev. Nutr. 1999, 19, 141–172. [CrossRef]
32. Bochar, D.A.; Staufacher, C.V.; Rodwell, V.W. Sequence comparisons reveal two classes of 3-hydroxy-3-
methylglutaryl coenzyme A reductase. *Mol. Genet. Metab.* 1999, 66, 122–127. [CrossRef]

33. Mizioro, H.M. Enzymes of the mevalonate pathway of isoprenoid biosynthesis. *Arch. Biochem. Biophys.* 2011, 505, 131–143. [CrossRef]

34. Jordan-Starck, T.C.; Rodwell, V.W. Role of cysteine residues in *Pseudomonas mevalonii* 3-hydroxy-3-
methylglutaryl-CoA reductase. Site-directed mutagenesis and characterization of the mutant enzymes. *J. Biol. Chem.* 1989, 264, 17919–17923.

35. Jordan-Starck, T.C.; Rodwell, V.W. *Pseudomonas mevalonii* 3-hydroxy-3-methylglutaryl-CoA reductase.
Characterization and chemical modification. *J. Biol. Chem.* 1989, 264, 17913–17918.

36. Darnay, B.G.; Wang, Y.; Rodwell, V.W. Identification of the catalytically important histidine of 3-hydroxy-
3-methylglutaryl-coenzyme A reductase. *J. Biol. Chem.* 1992, 267, 15064–15070.

37. Omkumar, R.V.; Darnay, B.G.; Rodwell, V.W. Modulation of Syrian hamster 3-hydroxy-3-methylglutaryl-CoA reductase activity by phosphorylation. Role of serine 871. *J. Biol. Chem.* 1994, 269, 6810–6814. [PubMed]

38. Istvan, E.S.; Palnitkar, M.; Buchanan, S.K.; Deisenhofer, J. Crystal structure of the catalytic portion of human HMG-CoA reductase: Insights into regulation of activity and catalysis. *EMBO J.* 2000, 19, 819–830. [CrossRef] [PubMed]

39. Vogeli, B.; Shima, S.; Erb, T.J.; Wagner, T. Crystal structure of archaeal HMG-CoA reductase: Insights into structural changes of the C-terminal helix of the class-I enzyme. *FEBS Lett.* 2019, 593, 543–553. [CrossRef] [PubMed]

40. Ragwan, E.R.; Arai, E.; Kung, Y. New crystallographic snapshots of large domain movements in bacterial 3-hydroxy-3-methylglutaryl coenzyme a reductase. *Biochemistry* 2018, 57, 5715–5725. [CrossRef] [PubMed]

41. Miller, B.R.; Kung, Y. Structural features and domain movements controlling substrate binding and cofactor specificity in class II HMG-CoA reductase. *Biochemistry* 2018, 57, 654–662. [CrossRef] [PubMed]

42. Sarver, R.W.; Bills, E.; Bolton, G.; Bratton, L.D.; Caspers, N.L.; Dunbar, J.B.; Harris, M.S.; Hutchings, R.H.; Kennedy, R.M.; Larsen, S.D.; et al. Thermodynamic and structure guided design of statin based inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase. *J. Med. Chem.* 2008, 51, 3804–3813. [CrossRef] [PubMed]

43. Pfefferkorn, J.A.; Choi, C.; Larsen, S.D.; Auerbach, B.; Hutchings, R.; Park, W.; Askew, V.; Dillon, L.; Hanselman, J.C.; Lin, Z.; et al. Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: Discovery of (3R,5R)-7-[2-(4-Fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic Acid (PF-3052334) as a candidate for the treatment of hyper. *J. Med. Chem.* 2008, 51, 31–45. [CrossRef] [PubMed]

44. Park, W.K.C.; Kennedy, R.M.; Larsen, S.D.; Miller, S.; Roth, B.D.; Song, Y.; Steinbaugh, B.A.; Sun, K.; Tait, B.D.; Kowala, M.C.; et al. Hepatoselectivity of statins: Design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors. *Bioorg. Med. Chem. Lett.* 2008, 18, 1151–1156. [CrossRef] [PubMed]

45. Pfefferkorn, J.A.; Song, Y.; Sun, K.L.; Miller, S.R.; Trivedi, B.K.; Choi, C.; Sorenson, R.J.; Bratton, L.D.; Unangst, P.C.; Larsen, S.D.; et al. Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitors. *Bioorg. Med. Chem. Lett.* 2007, 17, 4538–4544. [CrossRef] [PubMed]

46. Tabernero, L.; Rodwell, V.W.; Staufacher, C.V. Crystal structure of a statin bound to a class II hydroxymethylglutaryl-CoA reductase. *J. Biol. Chem.* 2003, 278, 19933–19938. [CrossRef] [PubMed]

47. Istvan, E.S.; Deisenhofer, J. Structural mechanism for statin inhibition of HMG-CoA reductase. *Science* 2001, 292, 1160–1164. [CrossRef] [PubMed]

48. Tabernero, L.; Bochar, D.A.; Rodwell, V.W.; Staufacher, C.V. Substrate-induced closure of the flap domain in the ternary complex structures provides insights into the mechanism of catalysis by 3-hydroxy-3-methylglutaryl–CoA reductase. *Proc. Natl. Acad. Sci. USA* 1999, 96, 7167. [CrossRef] [PubMed]

49. Istvan, E.S.; Deisenhofer, J. The structure of the catalytic portion of human HMG-CoA reductase. *Biochim. Biophys. Acta* 2000, 1529, 9–18. [CrossRef] [PubMed]

50. Berg, J.M.; Tymoczko, J.L.; Gatto, G.J.; Stryer, L. *Biochemistry*, 8th ed.; W.H. Freeman: New York, NY, USA, 2015; ISBN 1464126100. ISBN 9781464126109.

51. Brown, M.S.; Goldstein, J.L. A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. *Proc. Natl. Acad. Sci. USA* 1999, 96, 11041–11048. [CrossRef] [PubMed]

52. Kuwabara, P.E.; Labouesse, M. The sterol-sensing domain: Multiple families, a unique role? *Trends Genet.* 2002, 18, 193–201. [CrossRef] [PubMed]
53. Pfeffer, S.R. NPC intracellular cholesterol transporter 1 (NPC1)-mediated cholesterol export from lysosomes. *J. Biol. Chem.* 2019, 294, 1706–1709. [CrossRef]

54. Zhang, Y.; Bulkley, D.P.; Xin, Y.; Roberts, K.J.; Asarnow, D.E.; Sharma, A.; Myers, B.R.; Cho, W.; Cheng, Y.; Beachy, P.A. Structural basis for cholesterol transport-like activity of the hedgehog receptor patched. *Cell* 2018, 175, 1352–1364.e14. [CrossRef]

55. Ben Chorin, A.; Masrati, G.; Kessel, A.; Narunsky, A.; Sprinzak, J.; Lahav, S.; Ashkenazy, H.; Ben-Tal, N. ConSurf-DB: An accessible repository for the evolutionary conservation patterns of the majority of PDB proteins. *Protein Sci.* 2020, 29, 258–267. [CrossRef]

56. Oliveira, E.F.; Cerqueira, N.M.F.S.A.; Ramos, M.J.; Fernandes, P.A. QM/MM study of the mechanism of reduction of 3-hydroxy-3-methylglutaryl coenzyme A catalyzed by human HMG-CoA reductase. *Catal. Sci. Technol.* 2016, 6, 7172–7185. [CrossRef]

57. Gill, J.F., Jr.; Beach, M.J.; Rodwell, V.W. Mevolonate utilization in *Pseudomonas* sp. M. Purification and characterization of an inducible 3-hydroxy-3-methylglutaryl coenzyme A reductase. *J. Biol. Chem.* 1985, 260, 9393–9398.

58. Frimpong, K.; Rodwell, V.W. Catalysis by Syrian hamster 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Proposed roles of histidine 865, glutamate 558, and aspartate 766. *J. Biol. Chem.* 1994, 269, 11478–11483. [PubMed]

59. Osborne, T.F.; Gil, G.; Goldstein, J.L.; Brown, M.S. Operator constitutive mutation of 3-hydroxy-3-methylglutaryl coenzyme A reductase promoter abolishes protein binding to sterol regulatory element. *J. Biol. Chem.* 1988, 263, 3380–3387. [PubMed]

60. Rajavashisth, T.B.; Taylor, A.K.; Andalibi, A.; Svenson, K.L.; Lusis, A.J. Identification of a zinc finger protein that binds to the sterol regulatory element. *Science* 1989, 245, 640–643. [CrossRef] [PubMed]

61. Horton, J.D.; Goldstein, J.L.; Brown, M.S. SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver. *J. Clin. Invest.* 2002, 109, 1125–1131. [CrossRef] [PubMed]

62. Rawson, R.B.; DeBose-Boyd, R.; Goldstein, J.L.; Brown, M.S. Failure to cleave sterol regulatory element-binding proteins (SREBPs) causes cholesterol auxotrophy in Chinese hamster ovary cells with genetic absence of SREBP cleavage-activating protein. *J. Biol. Chem.* 1999, 274, 28549–28556. [CrossRef] [PubMed]

63. Yang, T.; Espenshade, P.J.; Wright, M.E.; Yabe, D.; Gong, Y.; Aebersold, R.; Goldstein, J.L.; Brown, M.S. Crucial step in cholesterol homeostasis: Sterols promote binding of SCAP to INSIG-1, a membrane protein that facilitates retention of SREBPs in ER. *Cell* 2002, 110, 489–500. [CrossRef]

64. Goldstein, J.L.; Rawson, R.B.; Goldstein, J.L.; Brown, M.S. Mutant mammalian cells as tools to delineate the sterol regulatory element-binding protein pathway for feedback regulation of lipid synthesis. *Arch. Biochem. Biophys.* 2002, 397, 139–148. [CrossRef]

65. Brown, M.S.; Ye, J.; Rawson, R.B.; Goldstein, J.L. Regulated intramembrane proteolysis: A control mechanism conserved from bacteria to humans. *Cell* 2000, 100, 391–398. [CrossRef]

66. Sever, N.; Yang, T.; Brown, M.S.; Goldstein, J.L.; DeBose-Boyd, R.A. Accelerated degradation of HMG CoA reductase mediated by binding of insig-1 to its sterol-sensing domain. *Mol. Cell* 2003, 11, 25–33. [CrossRef]

67. Sever, N.; Song, B.L.; Yabe, D.; Goldstein, J.L.; Brown, M.S.; DeBose-Boyd, R.A. Insig-dependent ubiquitination and degradation of mammalian 3-hydroxy-3-methylglutaryl-CoA reductase stimulated by sterols and geranylgeraniol. *J. Biol. Chem.* 2003, 278, 52479–52490. [CrossRef]

68. Faust, J.R.; Luskey, K.L.; Chin, D.J.; Goldstein, J.L.; Brown, M.S. Regulation of synthesis and degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase by low density lipoprotein and 25-hydroxycholesterol in UT-1 cells. *Proc. Natl. Acad. Sci. USA* 1982, 79, 5205–5209. [CrossRef] [PubMed]

69. Berkhourt, T.A.; Simon, H.M.; Patel, D.D.; Bentzen, C.; Niesor, E.; Jackson, B.; Suckling, K.E. The novel cholesterol-lowering drug SR-12813 inhibits cholesterol synthesis via an increased degradation of 3-hydroxy-3-methylglutaryl-enzyme A reductase. *J. Biol. Chem.* 1996, 271, 14376–14382. [CrossRef] [PubMed]

70. Roitelman, J.; Masson, D.; Avner, R.; Ammon-Zufferey, C.; Perez, A.; Guyon-Gellin, Y.; Bentzen, C.L.; Niesor, E.J. Apomine, a novel hypocholesterolemic agent, accelerates degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and stimulates low density lipoprotein receptor activity. *J. Biol. Chem.* 2004, 279, 6465–6473. [CrossRef] [PubMed]
71. Jiang, S.-Y.; Li, H.; Tang, J.-J.; Wang, J.; Luo, J.; Liu, B.; Wang, J.-K.; Shi, X.-J.; Cui, H.-W.; Tang, J.; et al. Discovery of a potent HMG-CoA reductase degrader that eliminates statin-induced reductase accumulation and lowers cholesterol. Nat. Commun. 2018, 9, 5138. [CrossRef] [PubMed] 

72. Toyota, Y.; Yoshioka, H.; Sagimori, I.; Hashimoto, Y.; Ohgane, K. Bisphosphonate esters interact with HMG-CoA reductase membrane domain to induce its degradation. Bioorg. Med. Chem. 2020, 28, 115576. [CrossRef] 

73. Li, M.-X.; Yang, Y.; Zhao, Q.; Wu, Y.; Song, L.; Yang, H.; He, M.; Gao, H.; Song, B.-L.; Luo, J.; et al. Degradation versus Inhibition: Development of proteolysis-targeting chimeras for overcoming statin-induced compensatory upregulation of 3-hydroxy-3-methylglutaryl coenzyme a reductase. J. Med. Chem. 2020, 63, 4908–4928. [CrossRef] 

74. Beg, Z.H.; Stonik, J.A.; Brewer, H.B., Jr. In vivo modulation of rat liver 3-hydroxy-3-methylglutaryl-coenzyme A reductase, reductase kinase, and reductase kinase kinase by mevalonolactone. Proc. Natl. Acad. Sci. USA 1984, 81, 7293–7297. [CrossRef] 

75. Panda, T.; Devi, V.A. Regulation and degradation of HMGCo-A reductase. Appl. Microbiol. Biotechnol. 2004, 66, 143–152. [CrossRef] 

76. Omkumar, R.V.; Rodwell, V.W. Phosphorylation of Ser871 impairs the function of His865 of Syrian hamster 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J. Biol. Chem. 1994, 269, 16862–16866. 

77. Chen, L.; Ma, M.-Y.; Sun, M.; Jiang, L.-Y.; Zhao, X.-T.; Fang, X.-X.; Man Lam, S.; Shui, G.-H.; Luo, J.; Shi, X.-J.; et al. Endogenous sterol intermediates of the mevalonate pathway regulate HMGCR degradation and SREBP-2 processing. J. Lipid Res. 2019, 60, 1765–1775. [CrossRef] 

78. Song, B.-L.; DeBose-Boyd, R.A. Insig-dependent ubiquitination and degradation of 3-Hydroxy-3-methylglutaryl coenzyme a reductase stimulated by δ- and γ-Tocotrienols. J. Biol. Chem. 2006, 281, 25054–25061. [CrossRef] [PubMed] 

79. Clarke, P.R.; Hardie, D.G. Regulation of HMG-CoA reductase: Identification of the site phosphorylated by the AMP-activated protein kinase in vitro and in intact rat liver. EMBO J. 1990, 9, 2439–2446. [CrossRef] 

80. Sato, R.; Goldstein, J.L.; Brown, M.S. Replacement of serine-871 of hamster 3-hydroxy-3-methylglutaryl-CoA reductase prevents phosphorylation by AMP-activated kinase and blocks inhibition of sterol synthesis induced by ATP depletion. Proc. Natl. Acad. Sci. USA 1993, 90, 9261–9265. [CrossRef] [PubMed] 

81. Hegsted, D.M. Serum-cholesterol response to dietary cholesterol: A re-evaluation. Am. J. Clin. Nutr. 1956, 1976, 299–305. [CrossRef] 

82. Brown, M.S.; Faust, J.R.; Goldstein, J.L.; Kaneko, I.; Endo, A. Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase. J. Biol. Chem. 1978, 253, 1121–1128. [PubMed] 

83. Endo, A.; Kuroda, M.; Tanzawa, K. Competitive inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett. 1976, 72, 323–326. [CrossRef] 

84. Endo, A.; Kuroda, M.; Tsujita, Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J. Antibiot. 1976, 29, 1346–1348. [CrossRef] 

85. Moorthy, N.S.H.N.; Cerqueira, N.M.F.S.A.; Ramos, M.J.; Fernandes, P.A. Ligand based analysis on HMG-CoA reductase inhibitors. Chemom. Intell. Lab. Syst. 2015, 140, 102–116. [CrossRef] 

86. Gotto, A.M., Jr. Results of recent large cholesterol-lowering trials and implications for clinical management. Am. J. Cardiol. 1997, 79, 1663–1666. [CrossRef] 

87. Hua, X.; Nohturff, A.; Goldstein, J.L.; Brown, M.S. Sterol resistance in CHO cells traced to point mutation in reductase kinase, and reductase kinase kinase by mevalonolactone. Proc. Natl. Acad. Sci. USA 1980, 77, 3957–3961. [CrossRef] [PubMed] 

88. Istvan, E.S. Structural mechanism for statin inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Am. Heart J. 2002, 144, S27–532. [CrossRef] [PubMed] 

89. Alberts, A.W.; Chen, J.; Kuron, G.; Hunt, V.; Huff, J.; Hoffman, C.; Rothrock, J.; Lopez, M.; Joshua, H.; Harris, E.; et al. Mevinolin: A highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc. Natl. Acad. Sci. USA 1980, 77, 3957–3961. [CrossRef] [PubMed] 

90. Tobert, J.A. Lovastatin and beyond: The history of the HMG-CoA reductase inhibitors. Nat. Rev. Drug Discov. 2003, 2, 517–526. [CrossRef] [PubMed]
91. Singh, N.; Tamariz, J.; Chamorro, G.; Medina-Franco, J.L. Inhibitors of HMG-CoA reductase: Current and future prospects. *Mini Rev. Med. Chem.* 2009, 9, 1272–1283. [CrossRef]

92. Wang, C.Y.; Liu, P.Y.; Liao, J.K. Pleiotropic effects of statin therapy: Molecular mechanisms and clinical results. *Trends Mol. Med.* 2008, 14, 37–44. [CrossRef]

93. Weitz-Schmidt, G. Statins as anti-inflammatory agents. *Trends Pharmacol. Sci.* 2002, 23, 482–487. [CrossRef]

94. Hassanabad, A.F. Current perspectives on statins as potential anti-cancer therapeutics: Clinical outcomes and underlying molecular mechanisms. *Transl. Lung Cancer Res.* 2019, 8, 692–699. [CrossRef]

95. Roca-Millan, E.; González-Navarro, B.; Izquierdo-Gómez, K.; Mari-Roig, A.; Jané-Salas, E.; López-López, J.; Velasco-Ortega, E. The application of statins in the regeneration of bone defects. Systematic review and meta-analysis. *Materials* 2019, 12, 2992. [CrossRef]

96. Ward Natalie, C.; Watts Gerald, F.; Eckel Robert, H. Statin toxicity. *Circ. Res.* 2019, 124, 328–350. [CrossRef]

97. Golomb, B.A.; Evans, M.A. Statin adverse events: A review of the literature and evidence for a mitochondrial mechanism. *Am. J. Cardiovasc. Drugs* 2008, 8, 373–418. [CrossRef]

98. Skottheim, I.B.; Gedde-Dahl, A.; Hejazifar, S.; Hoel, K.; Asberg, A. Statin induced myotoxicity: The lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro. *Eur. J. Pharm. Sci.* 2008, 33, 317–325. [CrossRef] [PubMed]

99. LaRosa, J.C. Low-density lipoprotein cholesterol reduction: The end is more important than the means. *Am. J. Cardiol.* 2007, 100, 240–242. [CrossRef] [PubMed]

100. Graham, D.J.; Staffa, J.A.; Shatin, D.; Andrade, S.E.; Schech, S.D.; La Grenade, L.; Gurwitz, J.H.; Chan, K.A.; Goodman, M.J.; Platt, R. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. *JAMA* 2004, 292, 2585–2590. [CrossRef] [PubMed]

101. Fuentes, A.V.; Pineda, M.D.; Venkata, K.C.N. Comprehension of top 200 prescribed drugs in the US as a resource for pharmacy teaching, training and practice. *Pharmacy* 2018, 6, 43. [CrossRef]

102. Oliveira, E.F.; Santos-Martins, D.; Ribeiro, A.M.; Brás, N.F.; Cerqueira, N.S.; Sousa, S.E.; Ramos, M.J.; Fernandes, P.A. HMG-CoA Reductase inhibitors: An updated review of patents of novel compounds and formulations (2011–2015). *Expert Opin. Ther. Pat.* 2016, 26, 1257–1272. [CrossRef]

103. Demierre, M.F.; Higgins, P.D.; Gruber, S.B.; Hawk, E.; Lippman, S.M. Statins and cancer prevention. *Am. J. Cardiol.* 2019, 124, 955–956. [CrossRef]

104. Fuentes, A.V.; Pineda, M.D.; Venkata, K.C.N. Comprehension of top 200 prescribed drugs in the US as a resource for pharmacy teaching, training and practice. *Pharmacy* 2018, 6, 43. [CrossRef]

105. Bjarnadottir, O.; Romero, Q.; Bendahl, P.O.; Jirstrom, K.; Ryden, L.; Loman, N.; Uhlen, M.; Johannesson, H.; Rose, C.; Jeter, R.; Bachmann, A.; Yount, S.T.; Shen, C.L.; Yeganehjoo, H. The potential of isoprenoids in cancer. *Molecules* 2020, 25, 3891. [CrossRef]

106. Pisanti, S.; Picardi, P.; Ciaglia, E.; D’Alessandro, A.; Bifulco, M. Novel prospects of statins as therapeutic agents in cancer. *Expert Opin. Ther. Pat.* 2016, 306–315. [CrossRef] [PubMed]

107. Bakke, P.; Aune, D.; Lagiou, P.; Darby, S.C.; Bueno-de-Mesquita, H.B.; Bojesen, S.E.; Overvad, K.; Khaw, K.T.; Virtue, A.; Khaw, K.T.; et al. Associations of lipophilic antioxidants and their metabolites with breast cancer risk: A nested case–control study. *Eur. J. Nutr.* 2019, 58, 1719–1729. [CrossRef]

108. Bjarnadottir, O.; Romero, Q.; Bendahl, P.O.; Jirstrom, K.; Ryden, L.; Loman, N.; Uhlen, M.; Johannesson, H.; Rose, C.; Grabau, D.; et al. Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial. *Breast Cancer Res. Treat.* 2013, 138, 499–508. [CrossRef] [PubMed]

109. Zhang, J.; Liu, Q. Cholesterol metabolism and homeostasis in the brain. *Protein Cell* 2015, 6, 254–264. [CrossRef] [PubMed]

110. Ridker, P.M.; Danielson, E.; Fonseca, F.A.H.; Genest, J.; Gotto, A.M.; Kastelein, J.J.P.; Koenig, W.; Libby, P.; Lorenzatti, A.J.; MacFadyen, J.G.; et al. Rosuvastatin to prevent vascular events: The ADDITION-P� trial. *Ann. Intern. Med.* 2013, 158, 695–705. [CrossRef]

111. van Heek, M.; Davis, H. Pharmacology of ezetimibe. *Eur. Heart J. Suppl.* 2002, 4, J5–J8. [CrossRef] [PubMed]
115. Rosenblum, S.B.; Huynh, T.; Afonso, A.; Davis, H.R., Jr.; Yumibe, N.; Clader, J.W.; Burnett, D.A. Discovery of 1-(4-fluorophenyl)-(3R)-(3-(4-fluorophenyl)-(3S)-hydroxypropyl)-(4S)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235): A designed, potent, orally active inhibitor of cholesterol absorption. *J. Med. Chem.* 1998, 41, 973–980. [CrossRef]

116. Garcia-Calvo, M.; Lisnock, J.; Bull, H.G.; Hawes, B.E.; Burnett, D.A.; Braun, M.P.; Crona, J.H.; Davis, H.R., Jr.; Dean, D.C.; Detmers, P.A.; et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). *Proc. Natl. Acad. Sci. USA* 2005, 102, 8132–8137. [CrossRef]

117. Rudel Lawrence, L.; Lee Richard, G.; Parini, P. ACAT2 Is a target for treatment of coronary heart disease associated with hypercholesterolemia. *Arterioscler. Thromb. Vasc. Biol.* 2005, 25, 1112–1118. [CrossRef]

118. Meuwese, M.C.; de Groot, E.; Duivenvoorden, R.; Trip, M.D.; Ose, L.; Maritz, F.J.; Basart, D.C.; Kastelein, J.J.; Habib, R.; Davidson, M.H.; et al. ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: The CAPTIVATE randomized trial. *JAMA* 2009, 301, 1131–1139. [CrossRef] [PubMed]

119. Lada, A.T.; Davis, M.; Kent, C.; Chapman, J.; Tomoda, H.; Omura, S.; Rudel, L.L. Identification of ACAT1- and ACAT2-specific inhibitors using a novel, cell-based fluorescence assay: Individual ACAT uniqueness. *J. Lipid Res.* 2004, 45, 378–386. [CrossRef] [PubMed]

120. Tian, S.; Siu, F.-M.; Lok, C.-N.; Fung, Y.M.E.; Che, C.-M. Anticancer auranofin engages 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) as a target. *Metallomics* 2019, 11, 1925–1936. [CrossRef] [PubMed]

121. Lin, S.-H.; Chang, D.-K.; Chou, M.-J.; Huang, K.-J.; Shiuan, D. Peptide inhibitors of human HMG-CoA reductase as potential hypocholesterolemia agents. *Biochem. Biophys. Res. Commun.* 2015, 456, 104–109. [CrossRef]

122. Zhang, J.; Ma, K.; Han, J.; Wang, K.; Chen, H.; Bao, L.; Liu, L.; Xiong, W.; Zhang, Y.; Huang, Y.; et al. Eight new triterpenoids with inhibitory activity against HMG-CoA reductase from the medical mushroom Ganoderma leucocontextum collected in Tibetan plateau. *Fitoterapia* 2018, 130, 79–88. [CrossRef]

123. Wang, K.; Bao, L.; Ma, K.; Zhang, J.; Chen, B.; Han, J.; Ren, J.; Luo, H.; Liu, H. A novel class of α-glucosidase and HMG-CoA reductase inhibitors from Ganoderma leucocontextum and the anti-diabetic properties of ganomycin I in KK-Ay mice. *Eur. J. Med. Chem.* 2017, 127, 1035–1046. [CrossRef]

124. Arantes, A.A.; Fale, P.L.; Costa, L.C.B.; Pacheco, R.; Ascensão, L.; Serralheiro, M.L. Inhibition of HMG-CoA reductase activity and cholesterol permeation through Caco-2 cells by caffeoylquinic acids from Vernonia condensata leaves. *Rev. Bras. Farmacogn.* 2016, 26, 738–743. [CrossRef]

125. Hartanti, L.; Yonas, S.M.K.; Mustamu, J.J.; Wijaya, S.; Setiawan, H.K.; Soegianto, L. Influence of extraction methods of bay leaves (Syzygium polyanthum) on antioxidant and HMG-CoA reductase inhibitory activity. *Heliyon* 2019, 5, e01485. [CrossRef]

126. Gesto, D.S.; Cerqueira, N.M.; Ramos, M.J.; Fernandes, P.A. Discovery of new druggable sites in the anti-cholesterol target HMG-CoA reductase by computational alanine scanning mutagenesis. *J. Mol. Model.* 2014, 20, 2178. [CrossRef]